CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 1,489 enrolled
Drug / intervention
Not specified
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02365922
NCT02365922N/ACompleted

Rare Diseases Clinical Research Network Advancing Research and Treatment for Frontotemporal Lobar Degeneration [ARTFL]: Research Projects 1 & 2

University of California, San Francisco·observational·Posted Feb 19, 2015·Updated May 21, 2021

In Brief

An observational study for FTLD and 11 related conditions. Completed, enrolled 1,489 participants across 17 sites in 2 countries.

Detailed Summary

Frontotemporal Lobar Degeneration (FTLD) is the neuropathological term for a collection of rare neurodegenerative diseases that correspond to four main overlapping clinical syndromes: frontotemporal dementia (FTD), primary progressive aphasia (PPA), corticobasal degeneration syndrome (CBS) and progressive supranuclear palsy syndrome (PSPS). The goal of this study is to build a FTLD clinical research consortium to support the development of FTLD therapies for new clinical trials. The consortium, referred to as Advancing Research and Treatment for Frontotemporal Lobar Degeneration (ARTFL), will be headquartered at UCSF and will partner with six patient advocacy groups to manage the consortium. Participants will be evaluated at 14 clinical sites throughout North America and a genetics core will genotype all individuals for FTLD associated genes.

Study Details

Timeline

N/ACompletedFinished
201520162017201820192020202120222023202420252026
First PostedFeb 19, 2015
Enrollment StartSep 1, 2014
Primary CompletionAug 1, 2020
Study CompletionSep 1, 2020
TodayJul 2, 2026
Enrollment to primary: 5.9 yearsPosted 11.4 years ago